Hims

Hims & Hers Health, Inc., doing business as hims, is an American telehealth and online pharmacy company headquartered in San Francisco, California. It provides prescription medications, over-the-counter medications and personal care products to consumers through a direct-to-consumer subscription model, with care delivered entirely online via video, phone or live chat consultations with licensed providers. The company began as Hims, a men's-health brand offering generic prescription treatments for erectile dysfunction and hair loss alongside skincare, and added the women's-focused Hers brand in 2018. Its current specialty areas include hair loss, sexual health (including erectile dysfunction, premature ejaculation and low testosterone), weight loss, mental health, dermatology/skin care and comprehensive lab testing with a provider-developed action plan covering ten areas of health.

The platform combines an e-commerce storefront with a clinical layer. Through the Hims mobile app (iOS, with Android available on Google Play and more than 1 million downloads), members book appointments, message licensed providers, manage shipments and subscriptions, order with one-click checkout, and access member pricing. The company has also built structured "Programs" — a curriculum developed with advisors and institutions, paired with coaches who provide step-by-step support during the first four weeks of a treatment and an online member community — positioned as an adherence tool in response to the stated problem that over half of US medical treatments are not taken correctly.

Since 2024 the company has been closely associated with GLP-1 weight-loss medicine, initially through compounded injectable semaglutide sold during a shortage of Novo Nordisk's branded Ozempic and Wegovy, and later through a short-lived branded Wegovy collaboration with Novo Nordisk. It has vertically integrated parts of its supply chain (a 503B compounding outsourcing facility) and expanded internationally through acquisitions in Europe, Australia, Canada and Japan.

Founding story

Andrew Dudum, born in 1988 and raised in San Francisco in a family of entrepreneurs, trained as a cellist before attending the Wharton School at the University of Pennsylvania to study management and economics. He founded the nonprofit microlending site LendforPeace while a student, then took leave (around 2009-2010) to join Sequoia-backed video-chat startup TokBox, which was later acquired (Dudum has described selling a company to Telefónica in 2012). In 2013 he co-founded Atomic Labs, a San Francisco venture studio backed by investors including Peter Thiel and Marc Andreessen, which builds companies with internal capital. Hims was conceived inside Atomic to de-stigmatize personal healthcare and simplify access; Dudum has said the name was chosen because expansion into women's health as "Hers" was always part of the plan [2][3][4].

Business model

Direct-to-consumer subscription commerce layered on a telehealth provider network: customers complete online consultations with licensed providers, receive prescriptions where eligible, and get medications and personal care products shipped on recurring subscriptions, with member-only pricing and app-based subscription management. Some offerings have been bundled with a monthly membership, as in the 2025 Wegovy collaboration [0][1][5].

Recurring subscription and product sales of prescription and over-the-counter medications and personal care items sold directly to consumers, plus memberships bundling access to branded medications; reported revenue of US$2.348 billion for 2025 [5].

Traction

Reported 2025 revenue of US$2.348 billion, operating income of US$105.6 million, net income of US$128.4 million and 2,442 employees; 2024 annual revenue of $1.48 billion. The company's site cites more than 500,000 existing members, and its Android app has over 1 million downloads. Acquired Eucalyptus, which had served more than 850,000 customers as of May 2026. Long-term targets are $6.5 billion revenue and $1.3 billion adjusted EBITDA by 2030 [0][1][2][5][6].

Latest developments

In April 2025 Hims & Hers announced a collaboration with Novo Nordisk to offer branded Wegovy bundled with a monthly membership; Novo Nordisk terminated it on June 23, 2025, citing the company's continued sale of compounded semaglutide, and the shares fell roughly 35%, prompting securities class actions in the Northern District of California. In June 2025 the company acquired ZAVA. In August 2025 Bloomberg reported an FTC investigation into advertising claims and subscription cancellation practices, and on September 9, 2025 the FDA issued a warning letter over website claims about compounded products. On February 5, 2026 the company launched a compounded oral semaglutide pill, withdrew it on February 7, 2026, and was sued by Novo Nordisk for patent infringement in Delaware on February 9, 2026. In March 2026 the two companies reached an agreement for Hims to sell Novo Nordisk weight-loss products on its platform. On June 2, 2026 Hims & Hers completed its acquisition of Eucalyptus, reaffirming 2030 targets of $6.5 billion revenue and $1.3 billion adjusted EBITDA [2][5][6].